Eosinophilic pneumonia - Causes, Treatment & When to See a Doctor

What is Eosinophilic pneumonia?

Eosinophilic pneumonia (EP) is an uncommon form of lung inflammation in which an abnormal number of eosinophils – a type of white blood cell that normally fights parasites and participates in allergic reactions – accumulate in the air spaces (alveoli) and interstitial tissue of the lungs. The excess eosinophils release inflammatory chemicals that damage the delicate lung structures, leading to symptoms such as cough, shortness of breath, and fever.

EP can be acute (developing over days to weeks) or chronic (gradual onset over months). In many cases the condition is reversible with prompt treatment, but delayed therapy can lead to respiratory failure or permanent lung scarring.

Common Causes

Most cases of eosinophilic pneumonia are secondary to another trigger. The following eight to ten conditions are the most frequently reported causes:

• Drug reactions – antibiotics (e.g., nitrofurantoin), anti‑seizure meds (phenytoin), NSAIDs, and certain antidepressants.
• Inhaled toxins – cigarette smoke, silica dust, or exposure to chemicals such as isocyanates.
• Parasitic infections – especially Ascaris lumbricoides, Strongyloides stercoralis, and Schistosoma species.
• Allergic bronchiolitis – often termed “acute eosinophilic pneumonia” (AEP) that occurs after recent high‑intensity exercise or recent initiation of smoking.
• Connective‑tissue diseases – systemic lupus erythematosus, rheumatoid arthritis, and vasculitides such as Churg‑Strauss syndrome (eosinophilic granulomatosis with polyangiitis).
• Idiopathic chronic eosinophilic pneumonia (ICEP) – no identifiable trigger; more common in middle‑aged women.
• Infections – certain viral (e.g., influenza) or bacterial infections can provoke an eosinophilic response.
• Radiation therapy – rare cases after thoracic irradiation.
• Occupational exposure – farmers, bird‑cage workers, or people handling moldy hay (farmer’s lung) can develop hypersensitivity‑type eosinophilic lung disease.
• COVID‑19‑related eosinophilic pneumonia – emerging reports describe eosinophilic infiltrates following SARS‑CoV‑2 infection or certain COVID‑19 vaccines.

Associated Symptoms

Eosinophilic pneumonia often mimics more common respiratory illnesses, which can delay diagnosis. Typical accompanying signs include:

• Fever (often >38 °C / 100.4 °F)
• Dry, non‑productive cough
• Shortness of breath that worsens with exertion
• Chest tightness or pleuritic pain
• Wheezing or crackles heard on auscultation
• Weight loss and fatigue (especially in chronic forms)
• Generalized muscle aches (myalgia)
• Peripheral eosinophilia – an elevated eosinophil count in the blood (usually >500 cells/µL)
• Occasional skin rash or arthralgia when EP is part of a systemic allergic reaction.

When to See a Doctor

Because EP can progress rapidly, anyone experiencing the following should seek medical attention promptly:

• New, unexplained fever and cough lasting more than 48 hours.
• Sudden worsening of shortness of breath, especially at rest.
• Chest pain that feels sharp or worsens with deep breathing.
• Persistent wheezing or noisy breathing despite use of a rescue inhaler.
• Unexplained weight loss or fatigue that interferes with daily activities.
• Known exposure to a potential trigger (new medication, dust, parasites) followed by respiratory symptoms.

Diagnosis

Diagnosing eosinophilic pneumonia involves a combination of clinical suspicion, laboratory testing, and imaging. The steps commonly used are:

1. Detailed medical history & physical exam

Clinicians ask about recent drug use, travel, occupational exposures, smoking history, and any underlying autoimmune disease.

2. Blood tests

• Complete blood count (CBC) – looks for peripheral eosinophilia.
• Serum IgE – often elevated in allergic‑type EP.
• Tests for parasites (stool ova & parasite exam, serology) when exposure is suspected.

3. Imaging

• Chest X‑ray – may show diffuse, bilateral infiltrates, often peripheral (“photographic negative” of pulmonary edema).
• High‑resolution CT (HRCT) scan – more sensitive; typical findings include ground‑glass opacities, consolidations with a peripheral or upper‑lobe predominance, and sometimes interlobular septal thickening.

4. Pulmonary function tests (PFTs)

Often reveal a restrictive pattern and reduced diffusion capacity (DLCO), supporting an interstitial process.

5. Bronchoscopy with bronchoalveolar lavage (BAL)

The gold‑standard diagnostic tool. A BAL fluid eosinophil count >25 % is highly suggestive of EP.

6. Lung biopsy (rare)

Reserved for cases where non‑invasive tests are inconclusive or when an alternative diagnosis (e.g., cancer, granulomatosis with polyangiitis) must be excluded.

7. Rule‑out other conditions

Physicians must differentiate EP from infections, pulmonary embolism, heart failure, and other interstitial lung diseases.

Treatment Options

The cornerstone of therapy is removing the inciting trigger and suppressing eosinophilic inflammation. Management can be divided into medical and supportive measures.

1. Discontinuation of offending agents

If a drug or inhaled toxin is identified, stopping exposure usually leads to rapid improvement.

2. Corticosteroids

• Acute eosinophilic pneumonia – intravenous methylprednisolone 0.5–1 mg/kg every 6 hours, then transition to oral prednisone 0.5 mg/kg/day.
• Chronic eosinophilic pneumonia – oral prednisone 0.5–1 mg/kg/day for 2–4 weeks, followed by a slow taper over 3–6 months to minimize relapse.
• Response is typically dramatic; most patients feel better within 48–72 hours.

3. Adjunct immunosuppressants

In steroid‑dependent or refractory cases, agents such as azathioprine, methotrexate, or mycophenolate mofetil may be added under specialist guidance.

4. Antiparasitic therapy

When a parasitic infection is confirmed, appropriate agents (e.g., albendazole for Strongyloides, praziquantel for Schistosoma) are prescribed.

5. Supportive care

• Oxygen supplementation for hypoxemia.
• Bronchodilators (short‑acting β‑agonists) if wheezing is present.
• Pulmonary rehabilitation once acute inflammation resolves.

6. Home measures

• Stay hydrated and rest while the lungs heal.
• Avoid smoking, second‑hand smoke, and dusty environments.
• Maintain a balanced diet rich in antioxidants (fruits, vegetables) to support immune health.

Prevention Tips

While not all cases are preventable, many risk factors can be mitigated:

• Medication awareness – inform your doctor of any previous allergic reactions; read drug labels for known eosinophil‑triggering agents.
• Occupational safety – use protective masks and proper ventilation when handling dust, chemicals, or animal dander.
• Pest control – avoid barefoot walking in areas where parasites are endemic; use approved anti‑parasitic prophylaxis when traveling to high‑risk regions.
• No smoking – tobacco and e‑cigarette vapor are common precipitants of acute EP.
• Allergy management – keep allergic rhinitis and asthma under control with inhaled steroids or antihistamines as prescribed.
• Vaccinations – stay up to date on flu and COVID‑19 vaccines; some case reports suggest severe viral infections can precipitate eosinophilic lung inflammation.

Emergency Warning Signs

Key Take‑aways

Eosinophilic pneumonia is a treatable lung disease characterized by an influx of eosinophils into the pulmonary tissue. Prompt recognition, removal of the trigger, and corticosteroid therapy usually lead to rapid recovery. However, because symptoms overlap with common infections, clinicians must maintain a high index of suspicion, especially in patients with recent drug exposure, occupational hazards, or parasitic risk. Patients should seek medical care early for persistent fever, cough, or breathing difficulty, and they must act urgently if severe respiratory distress occurs.

References:

• Mayo Clinic. “Eosinophilic pneumonia.” https://www.mayoclinic.org
• Cleveland Clinic. “Acute eosinophilic pneumonia.” https://my.clevelandclinic.org
• National Institutes of Health (NIH). “Eosinophilic Lung Diseases.” https://www.ncbi.nlm.nih.gov
• World Health Organization. “Prevention and control of parasitic infections.” https://www.who.int
• American Thoracic Society. “Guidelines for the diagnosis of eosinophilic lung disease.” https://www.thoracic.org